6kl6: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='6kl6' size='340' side='right'caption='[[6kl6]], [[Resolution|resolution]] 2.77Å' scene=''> | <StructureSection load='6kl6' size='340' side='right'caption='[[6kl6]], [[Resolution|resolution]] 2.77Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6kl6]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6KL6 OCA]. For a <b>guided tour on the structure components</b> use [http:// | <table><tr><td colspan='2'>[[6kl6]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Mers Mers]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6KL6 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6KL6 FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=DJU:N,N-dimethyl-1-(5-phenylmethoxy-1H-indol-3-yl)methanamine'>DJU</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DJU:N,N-dimethyl-1-(5-phenylmethoxy-1H-indol-3-yl)methanamine'>DJU</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6kl6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6kl6 OCA], [http://pdbe.org/6kl6 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6kl6 RCSB], [http://www.ebi.ac.uk/pdbsum/6kl6 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6kl6 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 23: | Line 23: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Mers]] | |||
[[Category: Hou, M H]] | [[Category: Hou, M H]] | ||
[[Category: Hsu, J N]] | [[Category: Hsu, J N]] | ||
Revision as of 10:16, 8 April 2020
Crystal structure of MERS-CoV N-NTD complexed with 5-BenzyloxygramineCrystal structure of MERS-CoV N-NTD complexed with 5-Benzyloxygramine
Structural highlights
Function[A0A0D3MU65_9BETC] Packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication.[SAAS:SAAS01160654] Publication Abstract from PubMedStructure-based stabilization of protein-protein interactions (PPIs) is a promising strategy for drug discovery. However, this approach has mainly focused on the stabilization of native PPIs, and non-native PPIs have received little consideration. Here, we identified a non-native interaction interface on the three-dimensional dimeric structure of the N-terminal domain of the MERS-CoV nucleocapsid protein (MERS-CoV N-NTD). The interface formed a conserved hydrophobic cavity suitable for targeted drug screening. By considering the hydrophobic complementarity during the virtual screening step, we identified 5-benzyloxygramine as a new N protein PPI orthosteric stabilizer that exhibits both antiviral and N-NTD protein-stabilizing activities. X-ray crystallography and small-angle X-ray scattering showed that 5-benzyloxygramine stabilizes the N-NTD dimers through simultaneous hydrophobic interactions with both partners, resulting in abnormal N protein oligomerization that was further confirmed in the cell. This unique approach based on the identification and stabilization of non-native PPIs of N protein could be applied toward drug discovery against CoV diseases. Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.,Lin SM, Lin SC, Hsu JN, Chang CK, Chien CM, Wang YS, Wu HY, Jeng US, Kehn-Hall K, Hou MH J Med Chem. 2020 Mar 11. doi: 10.1021/acs.jmedchem.9b01913. PMID:32105468[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||